Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...

This article was supported by Regione Veneto, Ricerca Sanitaria Finalizzata; Fondazione G Berlucchi per la Ricerca sul Cancro; Fondazione Cassa di Risparmio di Verona, Vicenza, Belluno e Ancona and ...

Faulty lipid regulation in CLL patients impairs T-cell function, affecting treatment outcomes and resistance to current therapies. Differences in lipid metabolism between CLL patients and healthy ...

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte. Lymphocytes are cells that help ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

There have been major treatment advancements for CLL in the last decade, with future generations of drugs on the horizon. When it comes to the treatment of chronic lymphocytic leukemia, or CLL, there ...

Research into immunotherapy against cancer typically focuses on better recognition of cancer cells by the body's own immune ...

In a recently published study, researchers at Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts ...

The prominent role of the BCR signaling in promoting B-CLL cell survival has prompted new therapeutic strategies targeted to signalosome elements. In particular, the most advanced BCR-signaling ...